BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies
Completed
BeiGene
Phase 1
2016-01-13
This study evaluated the safety and preliminary efficacy of BGB-3111 (zanubrutinib) in
combination with obinutuzumab in participants with B-cell lymphoid malignancies.
Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies
Completed
BeiGene
Phase 1
2016-06-29
This study is evaluating the safety and preliminary efficacy of BGB-3111 in combination with
BGB-A317 in participants with B-cell lymphoid malignancies.
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
Recruiting
Clinipace LTD
Phase 1
2016-10-01
A Three-Arm Study of ME-401 in Subjects with Relapsed/Refractory CLL/SLL or FL, of ME-401 in
Combination with Rituximab in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL, and of
ME-401 in Combination with Zanubrutinib in Subjects with Relapsed/Refractory CLL/SLL or
B-cell NHL
A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma
Recruiting
MEI Pharma, Inc.
Phase 1
2016-10-01
A Three-Arm Study of ME-401 in Subjects with Relapsed/Refractory CLL/SLL or FL, of ME-401 in
Combination with Rituximab in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL, and of
ME-401 in Combination with Zanubrutinib in Subjects with Relapsed/Refractory CLL/SLL or
B-cell NHL
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
